Matthias König: Developing an Open Whole-Body PBPK/PD Digital Twin of Apixaban
Matthias König, Associate Professor of Pharmacoepidemiology and Data Science at University of Southern Denmark, shared a post on LinkedIn about a recent preprint, he and his colleagues co-authored, published in Preprints.org, adding:
“New preprint: ‘An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics.’
In this work, we developed an open whole-body PBPK/PD digital twin of the direct oral anticoagulant apixaban, linking drug exposure to anticoagulation-related pharmacodynamic endpoints, including INR, PT, mPT, aPTT, and anti-Xa activity.
The model was built and evaluated using data from 35 curated clinical PK/PD studies, covering diverse dosing regimens and clinically relevant scenarios, including renal and hepatic impairment, food intake, and body weight effects.
It captures apixaban pharmacokinetics and pharmacodynamics across these populations and provides a reusable framework for personalised anticoagulant therapy.
A key focus was reproducibility and openness: all models, simulation workflows, documentation, and curated datasets are openly available and FAIR-compliant, enabling transparent reuse, independent verification, and future extension.
The work was developed as part of the Berlin University Alliance (BUA) X-Student Research Group ‘Digital Twins in Action:
Optimizing Direct Oral Anticoagulant Use’, funded by the Bundesministerium für Bildung und Forschung (BMBF) and the State of Berlin as part of the Excellence Strategy of the Federal and State Governments.”
Title: An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics
Authors: Mariia Myshkina, Mariia Babaeva, Linh Chang Nguyen, Shelee Bedón, Johannes Metternich, Michelle Elias, Matthias König

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders